NCT00003959View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

December 31, 2001

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
BIOLOGICAL

ras peptide cancer vaccine

BIOLOGICAL

sargramostim

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER